Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

One would have to expect the FDA to do this,with what Adxs is asking for. Or maybe the FDA should`ve just green stamped it without checking anything. Like I said earlier,if they`re changing the dosage strength,or frequency of dosing,or anything else to obtain a shorter trial with an earlier data read,this has to be double checked by the FDA,not just green stamped. It is a positive to me,because if the FDA is asking for more info,they`re considering approving the new design,,otherwise the news would`ve been that the FDA denies Adxs`s request for trial design revision. Period. As usual,the cup is always almost empty from the consensus here,never anything optimistic or positive.